

[163] ON LINE DATA & REAL TIME MONITORING OF PATIENTS RECEIVING INFUSION THERAPY

Michal Devir¹, Gershon Goldenberg¹, Pierre Sharvit¹, ¹ Pro-IV Medical

Investment Rational

PRO-IV's patented IoT system connects the patients receiving infusion therapy and their caregivers to the internet. It's proven technology improves dramatically the compliance and reduces errors by a unique management and monitoring system. It provides on-line information and real time reports for caregivers, homecare service providers, insurance companies. It also reduces re-admission costs. The company is led by Veteran entrepreneurs & executives.

Business Strategy

PRO-IV's IoT web based technology, is well suited for use in hospitals, outpatient clinics, nursing facilities, and home care. We plan to sell or license the software, and the controller devices. The company offers data management system and compliance call center. This diverse revenue structure will be attractive to customers depending on their reimbursement constraints.

Core Technology

The platform's main components include a controller device mounted on the IV line, a web-based management software, and smartphone App. The communication is done by 3G, NFC or wifi technology. Together, with its patient and drug ID systems, the system verifies patient/caregiver/medication, ensures compliance, provides real-time event management, and automatically documents all IV-related therapeutic events.

Product Profile/Pipeline

PRO-IV has developed three different products based on its basic technology, that addresses the needs of the different customers, such as homecare patients, healthcare providers, insurance companies, nursing homes outpatient clinics. Future pipeline includes product for the oncology market and 3G based products.

What's Next?

Pro-IV plans to launch its first product in the US market within 18 months. Near future goals include completion of an Israeli clinical study with a leading pharma company & healthcare company. Pro-IV is in discussion with a strategic partner in Europe. Agreement is expected next quarter. The company is currently raising funds to support the above activities.